Rating Change
Leerink Partners analysts upgraded Summit Therapeutics Inc. (NASDAQ:SMMT) from Underperform to Market Perform on August 12, 2026.
upgradeNASDAQ:SMMT
Summit Therapeutics Inc. (SMMT) Upgraded to Market Perform at Leerink Partners
Leerink Partners analysts upgraded Summit Therapeutics Inc. (NASDAQ:SMMT) from Underperform to Market Perform on August 12, 2026.
At publication ·
What changed
Summit Therapeutics Inc. (NASDAQ:SMMT) · upgrade
- Firm
- Leerink Partners
- Rating
- Underperform to Market Perform
- Price at event
- $15.10
- Market capitalization
- $13.4B
At a glance
Key takeaways
- Leerink Partners upgraded Summit Therapeutics (SMMT) from Underperform to Market Perform on August 12, 2026, suggesting analysts see improving fundamentals or a more favorable risk-reward profile.
Market Context
Summit Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $15.10 with a market capitalization of $13.4B. The stock has declined 43.4% over the past 52 weeks.
Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. Leerink Partners's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Summit Therapeutics Inc.
Among the 10 most recent ratings: 4 Buy, 5 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 12, 2026 | Leerink Partners | Market Perform | N/A |
| Jul 24, 2026 | Stifel | Buy | N/A |
| Jul 24, 2026 | Guggenheim | Buy | N/A |
| Jul 23, 2026 | HC Wainwright & Co. | Neutral | N/A |
| May 22, 2026 | HC Wainwright & Co. | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View SMMT Stock Page
Frequently Asked Questions
What does the Market Perform rating mean for SMMT?
A rating of Market Perform from Leerink Partners reflects the analyst's outlook on Summit Therapeutics Inc. (NASDAQ:SMMT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the SMMT forecast page.